Brief: Novartis Announces Commencement Of Tender Offer To Acquire Tourmaline Bio
29/09/2025 12:50
Sept 29 (Reuters) - NOVARTIS AG NOVN.S: NOVARTIS ANNOUNCES COMMENCEMENT OF TENDER OFFER TO ACQUIRE TOURMALINE BIO TORINO MERGER SUB INC COMMENCED A TENDER OFFER TO ACQUIRE ALL OF OUTSTANDING SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE OF TOURMALINE BIO, INC AT A PRICE OF $48 PER SHARE, IN CASH, WITHOUT INTEREST OFFER WILL EXPIRE AT ONE MINUTE FOLLOWING 11:59 P.M., NEW YORK CITY TIME, ON OCTOBER 27, 2025, UNLESS OFFER IS OTHERWISE EXTENDED Source text: ID:nGNE509hFG Further company coverage: NOVN.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Tourmaline Bio
See all newsBrief: Novartis Completes Acquisition Of Tourmaline Bio
Brief: Novartis Announces Expiration Of Tourmaline Bio Tender Offer
Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports (updated)
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Tourmaline Bio
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy